

HYBRIDOMAS SECRETING NOVEL MONOCLONAL ANTIBODIES AGAINST THE NUCLEOPROTEIN OF INFLUENZA VIRUS

Technology Summary

Influenza A viruses pose a serious threat to public health. The nucleoprotein (NP) of an influenza virus is a highly conserved protein involved in the transcription, replication and packaging of the viral genome, influencing the virulence of the virus within the host.

This invention is a hybridoma that secretes monoclonal antibodies that can broadly-react against the NP of influenza viruses. The antibodies, designated G20, A40 and A60, were specifically raised against the NP of the H3N2 virus A/Minnesota/11/2010.

Potential Commercial Applications

- Research tool
- Development of a clinical diagnostic for rapid detection of influenza virus infection

Competitive Advantages

- Broadly react with the NP of all tested subtypes of Influenza A viruses
- Antibody G20 has strong reactivity with the NP of equine H3N8 virus

Development Stage: Research reagent

Inventors: Hongquan Wan

Product Area: Bioassay, diagnostics, vaccine

FDA Reference No: E-2018-007

Licensing Contact:

Bill Ronnenberg, MS, JD/MIP
FDA Technology Transfer Program
Email: FDALicensing@fda.hhs.gov
Phone: 240-402-4561